Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07287748

A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

This trial consists of 2 parts, i.e., Part Ia and Ib. The Part Ia is to evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) refractory to or intolerant of standard-of-care therapy, who have received total thyroidectomy, and to determine the MTD (Maximum tolerated dose).

Part Ib is to evaluate the efficacy and safety of af-001 mutiple doses to patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma), who have received total thyroidectomy and are RAI naïve, randomized into two arms at the determined MTD or the MTD-1 dose level, and to determine the recommended Phase II dose (RP2D)

Recruiting

Interested in participating?

Request Info

Key information

Conditions

DTC - Differentiated Thyroid Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

National Cancer Center Hospital East

Kashiwa, Japan

Location status: Recruiting

About this study

The Part Ia is a dose escalation part. The Part Ib is a parallel-group comparative study part based on the MTD determined in Part Ia, in which 10 patients each will be randomly assigned to one of two treatment arms, at the MTD for af-001 or the MTD-1 dose level. Patients will be randomly assigned by the enrollment system (allocated at a ratio of 1:1). Random assignment will be performed using the stratified permuted block method. The stratification factor will be the site(s) of metastases.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

<Ia part>

  • Patients with differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) after total thyroidectomy.
  • Patients with radically unresectable, recurrent, metastatic disease who are judged by the principal investigator or sub-investigator (hereinafter, "principal/sub-investigators") to be refractory to or intolerant of standard-of-care therapy.

<Ib part>

  • Patients with radically unresectable, recurrent, metastatic disease who are RAI naive
  • Patients with measurable lesions. <Ia/Ib part>
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 and stable general condition.
  • Patients expected to survive for at least 6 additional months based on clinical symptoms and physical examination findings.

Exclusion criteria

<Ia/Ib part>

  • Patients who need to preserve fertility.
  • Females who are pregnant or may be pregnant, breastfeeding patients, or patients or their partners who cannot agree to appropriate contraception.
  • Patients with active multiple cancers (synchronous multiple cancers and ectopic double cancers with a disease-free period of <=3 years).
  • Patients with uncontrolled active infections.
  • Patients who are positive for hepatitis B virus surface (HBs) antigen, hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) antibodies.

Treatment and study plan

[211At]NaAt

Drug

MTD or MTD-1 level to be tested

Primary outcomes

  1. Ph1a: DLT (Dose-limiting toxicity ) based on Japanese translation of the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, Japan Clinical Oncology Group (JCOG) version

    Time frame: 4 weeks

    DLT evaluation criteria:

    • Grade ≥4* hematologic toxicity that persists for at least 7 days
    • Febrile neutropenia regardless of duration
    • Grade ≥3* thrombocytopenia associated with a bleeding tendency or that requires platelet transfusions
    • Anemia that requires red blood cell transfusions
    • Neutropenia associated with infection
    • Grade ≥3* non-hematologic toxicity that persists for at least 7 days and does not improve with symptomatic treatment, with the following exceptions:
    • Toxicities that can be controlled to Grade ≤2* with maximum supportive herapy
    • Those due to the progression of the primary tumor

    [*: Grades as defined in CTCAE v.5.0 (Japanese translation) JCOG version]

  2. Ph1b: Assessment of tumor reduction effect on MRI or CT scan images

    Time frame: 24 weeks

    Using the "Revised version of the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 (Japanese translation of JCOG version 1.0)" as a reference.

Study contacts

Contact information is provided by the study sponsor or research team.

Alpha Fusion Clinical Development

CONTACT

[email protected]

+81335185330

Sponsors and collaborators

Lead sponsor

Alpha Fusion Inc.

Industry

Registry information

Official study title

A Phase I Trial of the Alpha Particle-emitting Radiopharmaceutical, Af-001, in Patients With Differentiated Thyroid Cancer

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Dec 17, 2025
Registry last updated
Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.